Shots:

• The approval is based on P-III EMBRACA study results assessing Talzenna (qd- 1mg) vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) in 431 patients in ratio (2:1) with inherited BRCA1/2 mutation & LA or m-triple-negative or HR+/HER2- breast cancer- prior treated with 3L CT regimen
• The P-III EMBRACA study results: mPFS (8.6 mos.vs 5.6mos.); ORR (62.6% vs 27.2%); 46% reduction in the risk of disease progression
• Talzenna is a PARP inhibitor- being evaluated in multiple studies for breast and other cancers- including early triple-negative breast cancer and prostate cancer and has received FDA’s approval for gBRCAm HER2-- LA or m-breast cancer

Click here to read full press release/ article | Ref: Pfizer | Image: Q Costa Rica